Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation.

ABSTRACT: Objective:To study the prognostic value of neutrophil disorders in a retrospective cohort of high-grade glioma patients receiving definitive concurrent temozolomide and radiation. Materials and methods:Clinical records of consecutive patients treated in our Institution between January 2005 and December 2010 with concurrent temozolomide (75?mg/m2 daily) and radiation were collected. The prognostic value of pretreatment neutrophilia on survival, defined as a neutrophil count exceeding 7?G/L, was examined. Results:We identified 164 patients, all treated with concurrent temozolomide-based chemoradiotherapy. Initial surgery was achieved in most (75%), with resection?>?90% in 55 patients (34%). Total 151 patients (92%) had glioblastoma, and 13 patients (8%) had WHO grade III glioma. Eighty-two patients (50%) displayed pretreatment neutrophilia. Neutrophilia was not associated with concurrent or adjuvant temodal discontinuation (p?>?0.3). The 2-year actuarial overall survival was 45%. Steroid consumption, i.e. 60?mg or more of daily prednisolone, increased pretreatment neutrophil count (p?=?0.005). In univariate analysis, neutrophilia was associated with worse overall survival (p?=?0.019), as well as age???65?years (p?=?0.009), surgical resection?

SUBMITTER: Schernberg A 

PROVIDER: S-EPMC6008628 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature